Project Grant R44DK136377

Award Date 7/15/24
Completion Date 6/30/26
Dollars Obligated $2M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80303, USA
Similar Awards
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
This $274,547 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel Aneurysm Sealing Device (ASD) for endovascular treatment of Abdominal Aortic Aneurysms (AAA). The project seeks to create a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications and the need for repeat interventions. Key objectives include validating the device's adaptability...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $226,192 to Endonavis LLC, a small disadvantaged business located in Louisville, Kentucky. The grant supports the development of a novel over-the-scope platform for controlling variceal bleeding, a major complication of cirrhosis. The project aims to design a therapeutic...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,990 to Scorpido Photonics aims to develop a prototype endoscope-based diagnostic system for rapid, non-invasive detection of microscopic tumors. The project integrates plasmonic nanobubble sensors into a medical device platform and standard endoscope to enable instant, optical detection of cancerous tissues during lung cancer diagnostic procedures. The key product is a...
Eclipse Regenesis, Inc. received a $970,484 Project Grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program to develop a minimally invasive delivery method for their distraction enterogenesis device to treat short bowel syndrome. The device uses nondestructive tissue anchors and a spring to stretch the intestine and promote intestinal lengthening, restoring natural nutrient absorption in patients who currently rely on intravenous nutrition....
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,306 to Cutcath LLC to develop and evaluate a novel electrosurgical catheter device for treating acute aortic dissection. The device, called the Cutcath Dissection Septum Cutting Catheter (DSCC), aims to facilitate more effective endovascular aortic repair (TEVAR/EVAR) by allowing complete fenestration of the aortic dissection septum....
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $571,410 to Pharynvac Surgical Technology Inc. to develop a novel device called "Pharynvac" that can mitigate key issues in sinonasal surgeries. Specifically, the Pharynvac device aims to reduce surgical staff exposure to pathogens and toxins, prevent...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant awarded $274,440 to Vine Medical Inc., a for-profit manufacturing company, to develop a proof-of-concept for a self-deploying endotracheal intubation device. The proposed soft robotics system aims to achieve over a 90% first-pass intubation success rate, which would improve patient outcomes and reduce complications during emergency airway management procedures. The device is designed to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $838,162 to Averto Medical Inc. to conduct a clinical trial of the Coloseal ICD System, a novel medical device designed to eliminate the need for temporary ostomy surgeries in rectal cancer patients. The Coloseal ICD System is a minimally-invasive technology that can safely replace the function of temporary ostomies, which are commonly required for rectal cancer...

BALLOON OVERTUBE ACCESS DEVICE FOR IMPROVED INTERVENTIONAL ENDOSCOPY IN THE UPPER GI - PROJECT SUMMARY - ASPERO MEDICAL IS DEVELOPING AN INNOVATIVE, HIGHLY FLEXIBLE BALLOON OVERTUBE ACCESS DEVICE (BOAD) TO INCREASE THE ADOPTION AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) AND IMPROVE ENDOSCOPIC MUCOSAL RESECTION (EMR) IN THE UPPER GASTROINTESTINAL (GI) TRACT. CLINICALLY, ESD IS A RAPIDLY EMERGING APPROACH THAT IS PREFERRED OVER EMR FOR THE REMOVAL OF CANCEROUS AND PRECANCEROUS LESIONS IN THE UPPER GI (I.E., ESOPHAGUS AND STOMACH) BECAUSE IT OFFERS A HIGHER EN BLOC RESECTION RATE (91.7% VS. 46.7%), A HIGHER R0 RESECTION RATE (80.3% VS. 42.3%), AND A MUCH LOWER RECURRENCE RATE (0.9% VS. 12.2%). DESPITE THESE ADVANTAGES, LONGER PROCEDURE TIME, HIGHER RISK OF PERFORATION, AND TECHNICAL CHALLENGES OF USING THE REQUIRED TOOLS LEADS MANY INTERVENTIONAL ENDOSCOPISTS TO CHOOSE THE EASIER EMR TECHNIQUE OVER THE SUPERIOR ESD TECHNIQUE. THIS DISCONNECT BETWEEN CLINICAL BENEFIT AND CLINICAL PRACTICE PRESENTS AN OPPORTUNITY TO DRAMATICALLY IMPROVE PATIENT CARE BY INCREASING THE ADOPTION OF A WELL-ESTABLISHED, EVIDENCE-BASED TECHNIQUE THROUGH A NEW ENABLING DEVICE. IN THIS DIRECT-TO-PHASE II SBIR, ASPERO PROPOSES TO DESIGN AND TEST THE BOAD TO INCREASE THE ADOPTION OF ESD, COMPLETING DEVELOPMENT THROUGH PRECLINICAL TESTING AND DESIGN FREEZE, IN PREPARATION FOR VERIFICATION AND VALIDATION AND ULTIMATELY SUBMISSION OF A 510(K) APPLICATION FOR FDA CLEARANCE. THIS PROJECT BUILDS ON ASPERO'S PRIOR WORK, WHICH DEMONSTRATED AN INNOVATIVE PILLAR TEXTURED BALLOON OVERTUBE REDUCES SLIPPAGE DURING ENDOSCOPY PROCEDURES IN THE SMALL BOWEL, INCREASING ENDOSCOPE STABILITY. THE PROJECT ALSO BUILDS ON ASPERO'S INNOVATIVE C-TUBE DEVICE, WHICH IS THE FIRST COLONOSCOPY TOOL TO INCORPORATE AN ADDITIONAL WORKING CHANNEL WITH ROTATIONAL AND POSITIONAL CONTROL FOR THE USE OF A SECOND TOOL. ADAPTING THESE INNOVATIONS FOR USE IN THE UPPER GI AND COMBINING THEM WITH INTEGRATED HANDLE CONTROLS IS EXPECTED TO DELIVER A DEVICE THAT MITIGATES THE DISADVANTAGES OF ESD AND INCREASES ADOPTION OF THE PROCEDURE TO IMPROVE PATIENT OUTCOMES. AIM 1. PRODUCE AN INTEGRATED BALLOON AND OVERTUBE SHAFT DESIGN WITH INDEPENDENT WORKING CHANNEL AND USER-DEFINED HANDLE CONTROLS FOR UPPER GI USE. MILESTONE: DELIVER A DEVICE WITH INTEGRATED HANDLE CONTROLS THAT ACCOMMODATES MULTIPLE ENDOSCOPE SIZES, STABILIZES THE SURGICAL FIELD, INCORPORATES A SECOND WORKING CHANNEL FOR CONCURRENT TOOL USE, ALLOWS FOR INDEPENDENT ROTATION OF THE OVERTUBE AND ENDOSCOPE, AND INCORPORATES MICRO-POSITIONAL CONTROLS FOR A TOOL IN THE SECOND WORKING CHANNEL. AIM 2. ADVANCE BOAD TO DESIGN FREEZE IN PREPARATION FOR VERIFICATION, VALIDATION, AND FDA SUBMISSION. MILESTONES: CONFIRM USER ACCEPTANCE AND CLINICAL UTILITY OF THE DEVICE IN AN IN VIVO SIMULATED USE ANALYSIS. IMPACT-AT COMPLETION OF THIS PROJECT, ASPERO WILL BE POSITIONED TO THEN COMPLETE VERIFICATION AND VALIDATION TESTING OF THE BOAD THROUGH PHASE IIB AND/OR EXTERNAL SUPPORT, WHICH WILL FACILITATE 510(K) SUBMISSION. REAL-WORLD USE IS EXPECTED TO REDUCE ESD PROCEDURE TIME, REDUCE THE RISK OF PERFORATIONS, AND INCREASE ADOPTION BY INTERVENTIONAL ENDOSCOPISTS. INCREASED ADOPTION OF ESD IS EXPECTED TO REDUCE THE RECURRENCE RATE FOR LESIONS IN THE UPPER GI, RESULTING IN INCREASED OVERALL AND PROGRESSION-FREE SURVIVAL.

Posted 7/4/24